Brainstorm Cell Therapeutics Inc banner

Brainstorm Cell Therapeutics Inc
R&D

R&D · Mar 2025 report

R&D increased in the latest quarter

-$1.3m
+24.3%
-$4.7m
+56.7%
-$5m
+43.1% YoY

Quarterly R&D reached -$1.3m, down 35.7% year over year and up 24.3% sequentially; LTM R&D was -$5m, down 7.4% from the preceding LTM observation of -$4.7m.

Growth

Horizon Past Forecast Difference
Quarter N/A N/A
1 year N/A N/A
3-year CAGR N/A N/A
5-year CAGR N/A N/A
10-year CAGR N/A N/A

No analyst forecasts are available for R&D.

History

Statistic Value Reporting period
Average value -$10.1m Dec 2015 – Dec 2024
Median value -$9.5m Dec 2015 – Dec 2024
Highest value -$980k Dec 2017
Lowest value -$22.3m Dec 2020
Largest annual decline -$8.9m (-107.5%) Dec 2018 – Dec 2019

Brainstorm Cell Therapeutics Inc
R&D Peer Comparison

Brainstorm Cell Therapeutics Inc
Income Statement

USD
Metric FY2015 FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024
0 0 0 0 0 0 0 0 0 0
(8.5m) (5.1m) (5m) (14.1m) (23m) (31.7m) (24.5m) (24.8m) (21.4m) (11.7m)
(3.6m) (2.8m) (4m) (5.8m) (5.8m) (9.4m) (9.3m) (10.9m) (10.7m) (7m)
R&D
(5m) (2.3m) (980k) (8.3m) (17.2m) (22.3m) (15.2m) (14m) (10.7m) (4.7m)
(8.5m) (5.1m) (5m) (14.1m) (23m) (31.7m) (24.5m) (24.8m) (21.4m) (11.7m)
— — — — — — — — 4.7m 147k
50k 100k 50k 120k (250k) (130k) 80k 550k (447k) (77k)
(8.5m) (5m) (5m) (14m) (23.3m) (31.8m) (24.5m) (24.3m) (17.2m) (11.6m)
0 0 0 — — — — — — —
(8.5m) (5m) (5m) (14m) (23.3m) (31.8m) (24.5m) (24.3m) (17.2m) (11.6m)
(8.5m) (5m) (5m) (14m) (23.3m) (31.8m) (24.5m) (24.3m) (17.2m) (11.6m)
(0.46) (0.27) (0.26) (0.70) (1.06) (1.07) (0.68) (0.66) (5.99) (2.31)

Brainstorm Cell Therapeutics Inc
Glance View

Market Cap
9.8m USD
Industry
Biotechnology

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 20 full-time employees. The company went IPO on 2003-05-28. The firm is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The firm's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

BCLI Intrinsic Value

Create a free account · No card needed

What is Brainstorm Cell Therapeutics Inc's R&D?
R&D
-5m USD

Based on the financial report for Mar 31, 2025, Brainstorm Cell Therapeutics Inc's R&D amounts to -5m USD.

What is Brainstorm Cell Therapeutics Inc's R&D growth rate?
R&D CAGR 10Y
1%

Over the last year, the R&D growth was 43%. The average annual R&D growth rates for Brainstorm Cell Therapeutics Inc have been 28% over the past three years , 24% over the past five years , and 1% over the past ten years .

Back to Top